Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma
Brief Summary: To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma


Options:
A: Arm Label: Arm I (thalidomide); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Melphalan, Drug: Prednisone, Other: Quality-of-Life Assessment, Drug: Thalidomide | Arm Label: Arm II (lenalidomide); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Lenalidomide, Drug: Melphalan, Drug: Prednisone | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Arm II (lenalidomide) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (thalidomide) | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Arm I (thalidomide)
B: Arm Label: A (Thalidomide & Dexamethasone); Type: EXPERIMENTAL; Interventions: Drug: A (Thalidomide + Dexamethasone) | Arm Label: B (Dexamethasone and placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: B (Placebo + Dexamethasone) | Intervention Type: DRUG; Name: A (Thalidomide + Dexamethasone); Assigned to Arm(s): A (Thalidomide & Dexamethasone) | Intervention Type: DRUG; Name: B (Placebo + Dexamethasone); Assigned to Arm(s): B (Dexamethasone and placebo)
C: Arm Label: Bortezomib and Dexamethasone (VD); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Drug: Dexamethasone | Arm Label: Bortezomib, Thalidomide, and Dexamethasone (VTD); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Drug: Dexamethasone, Drug: Thalidomide | Arm Label: Bortezomib, Melphalan and Prednisone (VMP); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Drug: Melphalan, Drug: Prednisone | Intervention Type: DRUG; Name: Bortezomib; Assigned to Arm(s): Bortezomib and Dexamethasone (VD), Bortezomib, Melphalan and Prednisone (VMP), Bortezomib, Thalidomide, and Dexamethasone (VTD) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Bortezomib and Dexamethasone (VD), Bortezomib, Thalidomide, and Dexamethasone (VTD) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Bortezomib, Melphalan and Prednisone (VMP) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Bortezomib, Melphalan and Prednisone (VMP) | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Bortezomib, Thalidomide, and Dexamethasone (VTD)
D: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR

Answer: B